PAVmed (PAVM) Competitors

Neuronetics (NASDAQ:STIM) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.

Do institutionals and insiders hold more shares of STIM or PAVM?

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 19.9% of PAVmed shares are held by institutional investors. 9.8% of Neuronetics shares are held by insiders. Comparatively, 14.7% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more volatility & risk, STIM or PAVM?

Neuronetics has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Which has higher valuation & earnings, STIM or PAVM?

Neuronetics has higher revenue and earnings than PAVmed. Neuronetics is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$72.07M	0.33	-$30.19M	-$1.23	-0.64
PAVmed	$3.83M	2.96	-$64.18M	-$8.19	-0.13

Is STIM or PAVM more profitable?

Neuronetics has a net margin of -50.09% compared to PAVmed's net margin of -1,508.12%. PAVmed's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-50.09%	-118.17%	-30.33%
PAVmed	-1,508.12%	N/A	-102.44%

Does the MarketBeat Community prefer STIM or PAVM?

PAVmed received 74 more outperform votes than Neuronetics when rated by MarketBeat users. However, 68.45% of users gave Neuronetics an outperform vote while only 66.01% of users gave PAVmed an outperform vote.

Company	Underperform	Outperform
Neuronetics	Outperform Votes 128 68.45%	Underperform Votes 59 31.55%
PAVmed	Outperform Votes 202 66.01%	Underperform Votes 104 33.99%

Does the media favor STIM or PAVM?

In the previous week, Neuronetics had 5 more articles in the media than PAVmed. MarketBeat recorded 12 mentions for Neuronetics and 7 mentions for PAVmed. PAVmed's average media sentiment score of 0.60 beat Neuronetics' score of 0.10 indicating that PAVmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
PAVmed	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend STIM or PAVM?

Neuronetics presently has a consensus target price of $4.67, suggesting a potential upside of 490.72%. PAVmed has a consensus target price of $21.00, suggesting a potential upside of 1,826.61%. Given PAVmed's stronger consensus rating and higher probable upside, analysts plainly believe PAVmed is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
PAVmed	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Summary

Neuronetics beats PAVmed on 10 of the 19 factors compared between the two stocks.